Application of P450BM3 mutant in synthesis of steroid drugs

By protein engineering and directed evolution of the cytochrome P450BM3 mutant LG-23, combined with isopropanol dehydrogenase co-expression, its activity and selectivity in steroid drug catalysis, solving the problem of low activity. It has achieved efficient catalysis of a variety of steroidal drugs and has the potential for industrial application.

CN118909983AActive Publication Date: 2024-11-08HUBEI UNIV

Patent Information

Application Number
CN202310511313.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-08
Publication Date
2024-11-08
Estimated Expiration
2043-05-08

AI Technical Summary

Technical Problem

The existing cytochrome P450BM3 mutant LG-23 is less active when catalyzing steroidal drugs, cannot meet the yield requirements of industrial production, and has low conversion efficiency for non-natural substrates, which limits its widespread application.

Method used

Through protein engineering and directional evolution technology, LG-23 was subjected to multiple rounds of site-directed saturation mutations, and mutants with higher enzyme activity were obtained, and co-expressed with isopropanol dehydrogenase to improve the regeneration efficiency of NADPH and improve catalytic activity and selective.

Benefits of technology

It improves the C7β-position hydroxylation activity of steroids such as methylbisone and androstenedione, and has C11-position hydroxylation activity on 4 and 9 substances, reduces the production cost of steroid drugs and has the prospect of industrial development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004217594850000061
    Figure BDA0004217594850000061
  • Figure BDA0004217594850000101
    Figure BDA0004217594850000101
  • Figure BDA0004217594850000111
    Figure BDA0004217594850000111
Patent Text Reader

Abstract

The invention discloses a cytochrome P450BM3 mutant, the amino acid sequence of the cytochrome P450BM3 mutant is one of SEQ ID NOs: 1-3, the mutant can effectively catalyze a hydroxylation reaction of a substrate methyl diketone, androstenedione or 4, 9 substances to generate corresponding hydroxylated steroids C7beta-hydroxy methyl diketone, C7beta-hydroxy androstenedione and C11alpha-hydroxy 4, 9 substances, and the cytochrome P450BM3 mutant has excellent regioselectivity; and compared with the initial cytochrome P450BM3, the mutant has higher enzyme activity, and the production cost of related steroid drugs can be reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biocatalysis, and in particular relates to a cytochrome P450BM3 mutant and application thereof in synthesizing steroid drugs. Background Art

[0002] Steroidal drugs are among the most valuable and widely used drugs. Currently, a variety of steroidal drugs are widely used in various clinical diseases, including autoimmunity, inflammation, cancer, coronavirus infection, and osteoporosis. The introduction of different functional groups, such as hydroxyl groups, into the steroidal backbone in a regio- and stereoselective manner is crucial to the physiological and pharmacological activities of steroidal drugs.

[0003] In the synthesis of steroidal drugs, chiral hydroxylation reactions at specific positions are often catalyzed by enzymes or enzyme systems. Enzymes as catalysts are typically characterized by excellent regio- or stereoselectivity for natural substrates, but they may exhibit low thermal and solvent stability. Due to their narrow substrate spectrum, enzymes often exhibit specificity compared to chemical catalysts, which limits their broad applicability. Therefore, discovering or establishing an enzyme that catalyzes a specific reaction in commercially viable yields and sufficient purity is a challenging task.

[0004] Cytochrome P450 belongs to the superfamily of heme-containing enzymes and is widely present in nature. Cytochrome P450BM3 monooxygenase is a large, single-polypeptide protein of approximately 120 kDa. It is a single-component cytochrome P450 monooxygenase formed by the natural fusion of an oxidative domain and a reductase domain consisting of NADPH-dependent FAD and FMN. The heme domain is 55 kDa, and the flavin-dependent reductase domain is 65 kDa. The natural fusion of the heme and reductase domains results in a system with high electron transfer efficiency and speed, enhancing the catalytic activity of P450BM3. The turnover rate for its natural substrate is approximately 3000 times per minute, demonstrating high catalytic activity. However, the application of wild-type P450BM3 is limited to a certain extent because conversions involving non-natural substrates usually have low NADPH consumption rates and poor coupling efficiency, and exhibit low or even no activity towards larger steroid substrates and small substrate molecules such as cyclohexane, benzene (phenol), and benzyl alcohol.

[0005] P450BM3 is the most widely reported steroid hydroxylation agent. In 1997, the P450BM3 mutant F87A was reported to exhibit hydroxylation activity at C2β and C15β of testosterone, as well as C2β and C16β of progesterone. V. Rea, A. J. Kolkman, E. Vottero, et al. discovered that a key P450BM3 mutant, A82W, catalyzed steroidal hydroxylation of testosterone at the C16α / β position for the first time. Subsequently, Carlos G. Acevedo-Rocha, Charles G. Gamble, et al., building on this work, rationally designed an iterative saturation mutant library guided by information obtained from the mutational landscape and molecular dynamics simulations, developing a feasible directed evolution strategy. They achieved near-perfect stereo- and diastereoselective hydroxylation of five different steroids (testosterone, nandrolone, bolidiolone, androstenedione, and norethindrone) at the C16 position with high catalytic activity. Summary of the Invention

[0006] Our research group reported in the literature (Li A, Acevedo-Rocha CG, D'Amore L, et al., Regio-and Stereoselective Steroid Hydroxylation at the C7-Position by Cytochrome P450 Monooxygenase Mutants[J]. Angewandte Chemie International Edition, 2020.) that through DNA assembly and USER-based protein library construction technology, a centralized mutagenesis strategy was used to construct a mutant library that can simultaneously introduce up to 15 amino acid mutations in the center of the active pocket using the P450BM3 triple mutant (F87G / A328G / A330W) as a template. For the first time, the P450BM3 mutant LG-23 (amino acid sequence: SEQ ID NO: 7) containing 14 mutation sites with C7β-hydroxylation activity for eight steroid compounds was screened out. It has both high activity and high selectivity, filling the gap in steroid C7β-hydroxylation. The hydroxylation of steroids at the C7β position is used in the synthesis of a variety of steroidal drugs, including the anticancer drug fulvestrant, the cardiovascular drug eplerenone, and the diuretic spironolactone. However, when LG-23 catalyzes the steroidal reaction, only a few millimolar amounts of product are formed, resulting in low activity. This does not meet the production yield requirements for industrial production, hindering its industrial application.

[0007] In order to promote the application of LG-23 in steroid synthesis, its enzyme activity must be improved while maintaining its regio- and stereoselectivity. Therefore, we continued to modify LG-23 as the initial enzyme through protein engineering and directed evolution. After multiple rounds of site-directed saturation mutagenesis, we were fortunate to obtain some mutants with higher enzyme activity. They can hydroxylate steroids such as methyldione and androstenedione at the C7β position, and have C11 hydroxylation activity on 4,9 compounds, and have potential for industrial synthesis of related steroid drugs. We also used isopropanol dehydrogenase to regenerate and recycle the cofactor NADPH. By constructing a co-expression plasmid of isopropanol dehydrogenase and P450BM3 mutant and a co-expression strain containing the co-expression plasmid, we improved the catalytic activity of the P450BM3 mutant on steroids, replacing the additional addition of dehydrogenase and NADP. + The present invention comprises the following technical solutions:

[0008] The first aspect of the present invention provides a cytochrome P450BM3 mutant, which is a mutant formed by mutation of one or more, preferably two or more, of the following sites in the amino acid sequence of the original cytochrome P450BM3 (still abbreviated as LG-23 herein): Y51, G157, T260. The cytochrome P450BM3 mutant has the function of catalyzing the reaction of methyldiketone, androstenedione or 4,9-compound to produce C7β-hydroxymethyldiketone, C7β-hydroxyandrostenedione or C11α-hydroxy 4,9-compound, respectively.

[0009] Preferably, it is a mutant formed by one or more mutations selected from the following group: Y51I, G157S, T260G in the initial enzyme LG-23 amino acid sequence SEQ ID NO: 7.

[0010] Furthermore, its amino acid sequence is SEQ ID NO: 1, which is a T260G mutant of the initial enzyme LG-23, abbreviated herein as LG-23 / T260G; or its amino acid sequence is SEQ ID NO: 2, which is a Y51I / T260G mutant of the initial enzyme LG-23, abbreviated herein as LG-23 / Y51I / T260G; or its amino acid sequence is SEQ ID NO: 3, which is a Y51I / G157S / T260G mutant of the initial enzyme LG-23, abbreviated herein as LG-23 / Y51I / G157S / T260G.

[0011] The second aspect of the present invention is to provide a gene encoding the above-mentioned cytochrome P450BM3 mutant.

[0012] Preferably, the nucleotide sequence of the gene encoding the cytochrome P450BM3 mutant amino acid sequence SEQ ID NO:1, i.e., LG-23 / T260G, is SEQ ID NO:4, the nucleotide sequence of the gene encoding the cytochrome P450BM3 mutant amino acid sequence SEQ ID NO:2, i.e., LG-23 / Y51I / T260G, is SEQ ID NO:5, and the nucleotide sequence of the gene encoding the cytochrome P450BM3 mutant amino acid sequence SEQ ID NO:3 is SEQ ID NO:6.

[0013] The third aspect of the present invention is to provide a plasmid comprising the above-mentioned encoding gene. The plasmid can be a pET vector such as pET22b, pET24a, pET28a, or other vectors such as pSH plasmid and pRSFDuet plasmid.

[0014] The fourth aspect of the present invention is to provide a microorganism for expressing the above-mentioned cytochrome P450BM3 mutant, preferably the microorganism is a transformant transformed with the above-mentioned plasmid.

[0015] The above-mentioned microorganism can be selected from Escherichia coli, Bacillus subtilis, Pichia pastoris, and Saccharomyces cerevisiae, preferably Escherichia coli, and more preferably Escherichia coli BL21 (DE3).

[0016] The fifth aspect of the present invention is to provide the use of the above-mentioned cytochrome P450BM3 mutant or the above-mentioned microorganism in the production of steroid compounds.

[0017] As an optional embodiment, the above-mentioned microorganisms can be in the form of bacteria or cell fragments thereof.

[0018] In an exemplary application, methyldione, androstenedione or 4,9-compound is used as a substrate, and the above-mentioned cytochrome P450BM3 mutant or the above-mentioned microorganism is used to catalyze the hydroxylation reaction to produce the corresponding hydroxylated steroid C7β-hydroxymethyldione, C7β-hydroxyandrostenedione or C11α-hydroxy 4,9-compound, and the reaction formulas are (1), (4) and (5), respectively:

[0019] (1)

[0020] (4)

[0021] (5)

[0022] Furthermore, the above-mentioned application method also includes using 18-methadione, adrenosteroid, testosterone or nandrolone as substrates, using the cytochrome P450BM3 mutant or the microorganism to catalyze the hydroxylation reaction to generate the corresponding hydroxylated steroid C7β-hydroxy18-methadione, C7β-hydroxyadrenosteroid, C7β-hydroxytestosterone or C7β-hydroxynandrolone, and the reaction formulas are (6), (7), (8) and (9), respectively:

[0023] (6)

[0024] (7)

[0025] (8)

[0026] (9)

[0027] Optionally, the reaction system is added with glucose dehydrogenase, glucose and NADP + (nicotinamide adenine dinucleoside phosphate, coenzyme II) cofactor circulation system; or the above reaction system is added with alcohol dehydrogenase, isopropanol and NAD + (nicotinamide adenine dinucleotide, i.e. coenzyme I) cofactor circulation system.

[0028] Furthermore, the cytochrome P450BM3 can be co-expressed with glucose dehydrogenase or alcohol dehydrogenase in the cofactor circulation system in the same microbial strain.

[0029] The cytochrome P450BM3 mutants LG-23 / T260G, LG-23 / Y51I / T260G and LG-23 / Y51I / G157S / T260G obtained by genetic engineering mutation in the present invention have higher enzyme activity and excellent regional selectivity in catalyzing steroid hydroxylation reactions, and have a broad substrate spectrum; the constructed engineered strain can hydroxylate steroids such as methyldione and androstenedione at the C7β position, and has C11 hydroxylation activity for 4,9 compounds, thereby reducing the production cost of related steroid drugs and having prospects for industrial development. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 This is the HPLC spectrum of the reaction of methyl diketone catalyzed by LG-23 in Example 1.

[0031] Figure 2 This is the reaction situation of LG-23 / T260G in different cosolvents in Example 2.

[0032] Figure 3The plasmid map (A) for expressing LG23 / T260G, the plasmid map (B) for co-expressing LG23 / T260G and IPADHM4, and the whole-cell polyacrylamide gel electrophoresis pattern (C) in Example 4 are shown. Figure 3 M in C is a marker; lanes 1-3 are the supernatants of cell disruption of E. coli expression strains expressing IPADHM4 alone, co-expressing LG-23 / T260G+IPADHM4, and expressing LG-23 / T260G alone, respectively.

[0033] Figure 4 It is the product titer (concentration) of the methyl diketone reaction catalyzed by LG-23 / T260G under different cofactor regeneration systems.

[0034] Figure 5 C7β-hydroxymethyldiketone 1 H NMR (DMSO-d, 400 MHz) spectrum.

[0035] Figure 6 C7β-hydroxymethyldiketone 13 C NMR (DMSO-d, 400 MHz) spectrum.

[0036] Figure 7 The HSQC (DMSO-d, 400 MHz) spectrum of C7β-hydroxymethyldione is shown.

[0037] Figure 8 The HMBC (DMSO-d, 400 MHz) spectrum of C7b-hydroxymethyldione is shown.

[0038] Figure 9 The NOSY (DMSO-d, 400 MHz) spectrum of C7β-hydroxymethyldione is shown. DETAILED DESCRIPTION

[0039] In order to improve the enzymatic activity of the initial enzyme LG-23, the inventors selected amino acid sites around the active pocket for site-directed saturation mutagenesis based on a computer-simulated 3D model of the protein sequence, through rational analysis and semi-rational design, and obtained some mutants with improved enzyme activity, such as the (Y51I, G157S, T260G) mutants.

[0040] As used herein, the term "(enzyme activity) increase" or "increase" refers to an increase of at least 100% compared to a reference level, for example, an increase of at least 1-fold, at least 2-fold, or at least 3-fold, or at least 5-fold, or at least 10-fold, or at least 20-fold compared to a reference level.

[0041] The "mutation" includes, but is not limited to, replacement, deletion, insertion, chemical modification of amino acid residues, preferably a forward mutation, i.e., a mutation that improves enzyme activity. The substitution can be a non-conservative substitution, a conservative substitution, or a combination of a non-conservative substitution and a conservative substitution. "Conservative" amino acid substitutions or mutations refer to the interchangeability of residues with similar side chains, and therefore generally include substitutions of amino acids in the same or similar amino acid definition classes with amino acids in the polypeptide. However, as used herein, if a conservative mutation can instead be aliphatic to aliphatic, non-polar to non-polar, polar to polar, acidic to acidic, basic to basic, aromatic to aromatic, or restricted residue to restricted residue substitution, then a conservative mutation does not include substitutions of hydrophilic to hydrophilic, hydrophobic to hydrophobic, hydroxyl-containing to hydroxyl-containing, or small residue to small residue. As is well known in the art, common examples of conservative substitutions include: substitutions between aromatic amino acids F, W, and Y; substitutions between hydrophobic amino acids L, I, and V; substitutions between polar amino acids Q and N; substitutions between basic amino acids K, R, and H; substitutions between acidic amino acids D and E; and substitutions between hydroxyl amino acids S and T. Furthermore, A, V, L, or I can be conservatively mutated to another aliphatic residue or another non-polar residue. Exemplary conservative substitutions can be made, for example, according to the following table, where amino acids belonging to the same partition in the second column can be substituted for each other, and preferably, amino acids in the same row in the third column can be substituted for each other:

[0042]

[0043] "Non-conservative substitutions" refer to the substitution or mutation of an amino acid in a polypeptide with an amino acid having significantly different side chain properties. Non-conservative substitutions can use amino acids between, rather than within, the defined groups listed above. In one embodiment, a non-conservative mutation affects (a) the structure of the peptide backbone in the region of the substitution (e.g., proline for glycine), (b) charge or hydrophobicity, or (c) side chain bulk.

[0044] "Deletion" refers to a modification of a polypeptide by removing one or more amino acids from a reference polypeptide. Deletion can include the removal of 1 or more amino acids, 2 or more amino acids, 5 or more amino acids, 10 or more amino acids, 15 or more amino acids, or 20 or more amino acids, up to 10% of the total number of amino acids comprising the reference enzyme, while retaining enzymatic activity and / or retaining the improved properties of the engineered aldolase. Deletions can be directed to the interior and / or ends of the polypeptide. In various embodiments, deletions can comprise continuous segments or can be discontinuous.

[0045] "Insertion" refers to the modification of a polypeptide by adding one or more amino acids from a reference polypeptide. In some embodiments, the improved engineered aldolase enzymes include the insertion of one or more amino acids into naturally occurring aldolase enzymes and the insertion of one or more amino acids into other improved aldolase polypeptides. The insertion can be internal to the polypeptide, or at the carboxyl or amino termini. As used herein, insertion includes fusion proteins as known in the art. The insertion can be a continuous amino acid segment or separated by one or more amino acids from a naturally occurring polypeptide.

[0046] In order to perform site-directed mutagenesis, a three-dimensional model of cytochrome P450BM3 was constructed (modeled) based on bioinformatics technology to infer its enzyme catalytic active center, active pocket, substrate / product entry and exit channels, rigid / flexible structural regions, etc., and possible structural influencing sites were selected and saturation mutagenesis was attempted.

[0047] As used herein, the terms "initial (type)", "initial (monooxygenase)," and "initial (monooxygenase)" have the same meaning and refer to the cytochrome P450BM3 mutant LG-23 having the amino acid sequence of SEQ ID NO: 7. For the sake of convenience, the initial type cytochrome P450BM3 and its mutants may be collectively referred to as "cytochrome P450BM3" herein.

[0048] The amino acid sequence of the cytochrome P450BM3 mutant of the present invention is clear, so those skilled in the art can easily obtain its encoding gene, expression cassettes and plasmids containing these genes, and transformants containing the plasmids.

[0049] In order to optimally express cytochrome P450BM3 or its mutants in Escherichia coli, which is the most commonly used bacterium in genetic engineering, the genes expressing these enzymes can be codon-optimized.

[0050] Codon optimization is a kind of technology that can be used for making protein expression in organism maximized by increasing the translation efficiency of gene of interest.Different organisms usually illustrate the special preference for one of some codons of the same amino acid of coding due to mutation tendency and natural selection.For example, in fast-growing microorganisms such as intestinal bacteria, the composition of its genome tRNA library separately is reflected by optimizing codon.Therefore, in fast-growing microorganisms, the low frequency codon of amino acid can be used for the codon displacement of the same amino acid but high frequency.Therefore, the expression of optimized dna sequence dna is improved in fast-growing microorganisms.

[0051] For example, to express cytochrome P450BM3 in E. coli, the encoding gene of the codon-optimized mutant LG-23 / T260G can be SEQ ID NO: 4; the encoding gene of the mutant LG-23 / Y51I / T260G can be SEQ ID NO: 5; and the encoding gene of the mutant LG-23 / Y51I / T260G can be SEQ ID NO: 6.

[0052] These genes, expression cassettes, plasmids, and transformants can be obtained through genetic engineering construction methods well known to those skilled in the art.

[0053] The transformant host can be any microorganism suitable for expressing cytochrome P450BM3, including bacteria and fungi. Preferably, the microorganism is Bacillus subtilis, Pichia pastoris, Saccharomyces cerevisiae, or Escherichia coli, preferably Escherichia coli, more preferably Escherichia coli BL21 (DE3).

[0054] When used as a biocatalyst, the cytochrome P450BM3 of the present invention can be in the form of an enzyme or a bacterial cell. The enzyme forms include free enzymes, immobilized enzymes, including purified enzymes, crude enzymes, fermentation broths, and enzymes immobilized on carriers; the bacterial cell forms include living cells, dead cells, and immobilized cells.

[0055] As another optional embodiment, microbial cells expressing the aforementioned cytochrome P450BM3 can be used as biocatalysts for enzyme-catalyzed reactions. The microorganisms can be in the form of cells or cell fragments thereof, including both living and dead cells. This is because when microorganisms such as Bacillus subtilis, Pichia pastoris, Saccharomyces cerevisiae, or Escherichia coli are no longer fermented and proliferated but are instead used for enzyme-catalyzed reactions, they themselves become natural immobilized enzymes and do not require fragmentation or even extraction and purification processes to be used as enzyme preparations for catalytic reactions. Because both the reaction substrates and reaction products are small molecules that can easily pass through the cell membrane, the biological barrier of the cell, fragmentation of the cell is not necessary, which is economically advantageous.

[0056] What is more advantageous is that many microbial cells contain some coenzymes such as NADP + (nicotinamide adenine dinucleoside phosphate, coenzyme II) or NAD + (nicotinamide adenine dinucleotide, i.e. coenzyme I), can effectively promote the redox reaction, without the need for or reducing the need to add expensive coenzymes to the enzyme-catalyzed reaction system.

[0057] In the application of cytochrome P450BM3 mutants for catalytic synthesis of steroid compounds, a cofactor regeneration system can be added to the reaction system. As a preferred embodiment, when cytochrome P450BM3 and glucose dehydrogenase (GDH) are used for combined catalysis, glucose can be added to the reaction system as a substrate for glucose dehydrogenase. During the reaction, glucose dehydrogenase catalyzes the oxidation of glucose and simultaneously converts (NADP + )NAD + The enzyme is reduced to (NADPH)NADH, and cytochrome P450BM3 and NAD(P)H catalyze the hydroxylation of the substrate. The amount of glucose dehydrogenase and glucose added can be determined by simple experiments.

[0058] As another optional embodiment, when a cytochrome P450BM3 mutant and alcohol dehydrogenase are used for combined catalysis, isopropanol can be added to the reaction system as a substrate for the alcohol dehydrogenase. During the reaction, the alcohol dehydrogenase catalyzes the oxidation of isopropanol and simultaneously converts (NADP + )NAD + The hydroxylation of the substrate is catalyzed by cytochrome P450BM3 and NAD(P)H. The amount of alcohol dehydrogenase and isopropanol to be added can be determined by simple experiments.

[0059] It is easy for those skilled in the art to understand that the glucose dehydrogenase and alcohol dehydrogenase can be provided in the form of enzymes or in the form of expression microorganisms.

[0060] In an optional embodiment, cytochrome P450BM3 can be co-expressed with glucose dehydrogenase (GDH) or alcohol dehydrogenase (ADH) in the same strain, thereby eliminating the trouble of adding the two enzymes or expression cells in proportion in the catalytic reaction system.

[0061] The present invention will be further described in detail below with reference to specific examples. It should be understood that the following examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention.

[0062] Example

[0063] This article involves the addition amount, content and concentration of various substances, and the percentages mentioned therein, unless otherwise specified, refer to the percentage by mass.

[0064] Materials and methods

[0065] The whole gene synthesis, primer synthesis and sequencing in the examples were commissioned to Sangon Biotech (Shanghai) Co., Ltd.

[0066] The molecular biology experiments in the examples, including plasmid construction, enzyme digestion, ligation, competent cell preparation, transformation, culture medium preparation, etc., were performed primarily with reference to the third edition of Molecular Cloning: A Laboratory Manual (J. Sambrook, D.W. Russell, USA, translated by Huang Peitang et al., Science Press, Beijing, 2002). Specific experimental conditions can be determined by simple experiments if necessary.

[0067] PCR amplification experiments should be performed according to the reaction conditions provided by the plasmid or DNA template supplier or the kit instructions. These conditions can be adjusted through simple experiments if necessary.

[0068] LB medium: 10 g / L tryptone, 5 g / L yeast extract, 10 g / L sodium chloride, pH 7.2. (Add 20 g / L agar powder to LB solid medium.)

[0069] TB medium: 24g / L yeast extract, 12g / L tryptone, 16.43g / L K2HPO4.3H2O, 2.31g / L KH2PO4, 5g / L glycerol, pH 7.0-7.5. (TB solid medium should also contain 20g / L agar powder.)

[0070] Compounds such as methyldione, androstenedione, 4,9-dione, 18-dione, adrenosterone, testosterone, and nandrolone were purchased from Sigma-Aldrich.

[0071] HPLC detection method of substrate and product:

[0072] All samples were analyzed by Shimadzu high-performance liquid chromatography (LC-2030 or LC-2030C). An Agilgnt ZORBAX SB C18 (250 × 4.6 mm) column was used with methanol, acetonitrile, and ultrapure water as the mobile phases. Methyldione, androstenedione, and 4 and 9 compounds were analyzed using the following method: a flow rate of 1.5 mL / min, methanol:acetonitrile:ultrapure water, a 1-minute (15:15:70) mixture, a 1- to 2-minute (20:20:60) mixture, a 2- to 7-minute (35:35:30) mixture, and a 7- to 10-minute (15:15:70) mixture. The detection wavelength was 250 nm, and the detection wavelength for 4 and 9 compounds was 310 nm.

[0073] The identification of the reaction products C7β-hydroxymethyldione, C7β-hydroxyandrostenedione, C7β-hydroxy18-methyldione, C7β-hydroxyadrenosterone, C7β-hydroxytestosterone, and C7β-hydroxynandrolone was also reported in the literature Li A, et al., Regio-and Stereoselective Steroid Hydroxylation at the C7-Position by CytochromeP450Monooxygenase Mutants[J]. Angewandte Chemie International Edition, 2020.; the identification of C11α-hydroxy 4,9-compound was also reported in the literature Peng Yaqin, Gao Chenghua, Zhang Zili, et al. A Chemoenzymatic Strategy for the Synthesis of Steroid Drugs Enabled byP450Monooxygenase-Mediated Steroidal Core Modification[J]. ACS Catalysis, 2022, 12(5): 2907-14.

[0074] It should be noted that, for the sake of convenience of description, in the embodiments, the strain number, plasmid number, enzyme number, and enzyme-encoding gene number may share one number, which is easily understood by those skilled in the art, that is, the same number can refer to different biological forms in different environments.

[0075] The plasmids expressing cytochrome P450BM3 in the examples, such as pRSFDuet-LG-23, and the plasmids used for gene editing operations were all constructed and preserved by Li Aitao's research group at the School of Life Sciences of Hubei University. Any unit or individual can obtain the plasmids for verification of the present invention, but they may not be used for other purposes, including development, utilization, scientific research, and teaching, without the permission of Hubei University.

[0076] Example 1: Site-directed saturation mutagenesis and functional verification of the P450 BM3 enzyme mutant LG-23

[0077] 1.1 Site-directed saturation mutagenesis of mutant LG-23

[0078] In this example, based on the P450BM3 enzyme mutant LG-23 with steroid 7β-hydroxylation activity (Li A, et al., Regio-and Stereoselective Steroid Hydroxylation at the C7-Position by Cytochrome P450 Monooxygenase Mutants[J]. Angewandte Chemie International Edition, 2020.), the plasmid vector pRSFDuet-LG-23 expressing the mutant LG-23 was used as a template, and amino acid sites around the active pocket in the enzyme model were selected. The mutant LG-23 gene was subjected to site-directed saturation mutagenesis using primer PCR mutagenesis technology. The plasmid vector pRSFDuet-LG-23 was constructed by our research group (ibid.), and its structural map is shown in FIG. Figure 3 Some primers are shown in Table 1 below, where the screening of T260 mutants is used as an example.

[0079] Table 1: Primer sequences for site-directed saturation mutagenesis of LG-23

[0080]

[0081]

[0082] Note: The suffix "F" in the primer name stands for forward; "R" stands for reverse.

[0083] The PCR system (20 μL) was as follows: 0.1-1 ng of template, 1 μL of each pair of mutation primers (10 μM), 5 μL of PrimeSTARMax DNA polymerase, and sterile distilled water was added to 20 μL.

[0084] The PCR reaction program was as follows: pre-denaturation at 98°C for 3 min, followed by 29 cycles of denaturation at 98°C for 10 sec, annealing at 56°C for 15 sec, and extension at 72°C for 80 sec, and finally extension at 72°C for 5 min. The PCR product was stored at 8°C.

[0085] The amplified PCR product was detected by 0.7% agarose gel electrophoresis, and a band of the same length as the pRSFDuet-LG-23 plasmid was observed. It was judged that the gene encoding the target mutant had been amplified. Therefore, the restriction endonuclease Dpn I was added to the PCR product, digested at 37°C for 3-5 hours, and then transformed into E. coli BL21 (DE3) competent cells. After adding culture medium for 1 hour, it was evenly coated on a solid LB plate containing 50 μl / mg kanamycin. An eight-row electric gun (Gilson, P8x1200M) was used to add 400 μL of liquid LB (50 μg / mL, Kanamycin) to the sterilized 96-well deep-well plate. + ) culture medium, pick the initial strain monoclonal clone to the A1 well, and the A2 well is a blank control. Pick the monoclonal strain on the transformation plate to a 96-well plate, and pick 94 monoclonal clones from each plate to other positions of the 96-well deep-well plate (the same 96-well deep-well plate only contains a single-site NNK saturation mutation), and culture it in a 37°C, 800rpm high-frequency shaking shaker for 10-12 hours. Then take a 200μL aliquot and transfer it to each plate containing 200μL 50% (v / v) glycerol reserve plates, and store them in a -80°C low-temperature freezer. Add 800μL TB culture medium (add a final concentration of 0.2mM IPTG and 50μg / mL kanamycin sulfate in advance) to the remaining 200μL culture and induce expression for 16-18h in a high-frequency shaking shaker. The bacterial solution induced for 16-18 hours was centrifuged at 4000 rpm and 8°C for 10 minutes to obtain the cell pellet, which was resuspended and washed once with 400 μL potassium phosphate buffer (100 mM, pH 8.0), and the supernatant was discarded. Subsequently, 200 μL potassium phosphate buffer (100 mM, pH 8.0) was added and resuspended, and the plate was quickly frozen using liquid nitrogen. The quick-frozen 96-well plate was stored in a -80°C low-temperature freezer until further use as a cell catalyst.

[0086] Take out the 96-well deep-well plate containing the saturated mutation site of the P450BM3 mutant after induction expression from the -80℃ low-temperature freezer and thaw it at room temperature. + All cells were resuspended in 200 μL phosphate buffer (100 mM, pH 8.0) containing 2 U / mL glucose dehydrogenase (GDH) to make the final reaction system contain 3% w / v glucose, 10% v / v glycerol, 0.2 mM NADP +, 400 μL phosphate-buffered cell resuspension containing 1 U / mL GDH. Add a certain concentration of substrate. Start the reaction on a high-speed shaking shaker at 25°C and 800 rpm until the reaction time reaches 12-18 hours. Add 400 μL methanol to extract the reaction mixture and centrifuge at 4000 rpm and 4°C for 10 minutes. Use a wwPTFE 96-well plate filter to remove solid particles by centrifugation (Pall, VWR, Germany) and filter the supernatant into a new 200 μL 96-well plate dedicated to high-performance liquid chromatography analysis. Seal the 96-well plate with a silicon cap and perform HPLC analysis. All samples were analyzed by Shimadzu high-performance liquid chromatography (LC-2030 or LC-2030C). Mutant strains with improved activity relative to LG-23 were obtained and rescreened.

[0087] The reaction equation for the C7β hydroxylation of methyl diketone catalyzed by P450 BM3 mutants LG-23 and LG-23 / T260G is shown in (1).

[0088] (I)

[0089] Figure 1 The HPLC profile of the reaction of methyldiketone catalyzed by the initial enzyme LG-23 cells is shown.

[0090] Figure 5-Figure 9 The C7β-hydroxymethyl diketone 1 H NMR (DMSO-d, 400 MHz) spectrum, 13 CNMR (DMSO-d, 400 MHz) spectrum, HSQC (DMSO-d, 400 MHz) spectrum, HMBC (DMSO-d, 400 MHz) spectrum and NOSY (DMSO-d, 400 MHz) spectrum.

[0091] The NMR data of C7β-hydroxymethyl diketone are as follows:

[0092] 1H NMR(DMSO-d6,400MHz): δ5.75(1H,s,H-4),4.76(1H,d,6.4Hz,7-OH),3.33(1H,m,H-7),2.62(1H,dd,13.8,4.6Hz,H-6a),2.34(1H,dd,19.2,8.7Hz,H-16 a),2.25(1H,overlapped,H-16a),2.24(1H,overlapped,H-6b),2.21(2H,overlapped,H-2a,H-2b),2.18(1H,overlapped,H-1b),2.15(1H,overlapped ,H-10),1.97(1H,dd,19.2,9.0Hz,H-16b),1.84(1H,m,H-11a),1.77(1H,m, H-15b),1.64(1H,dt,12.7,3.2Hz,H-12a),1.51(1H,q,10.0Hz,H-8),1.43(1 H,dd,11.6,5.5Hz,H-14),1.39(1H,m,H-1b),1.28(1H,td,12.7,3.8Hz,H-11 b),1.15(1H,td,12.7,4.1Hz,H-12b),0.86(3H,s,H3-18),0.84(1H,m,H-9);

[0093] 13 C NMR(DMSO-d6,100MHz): δ220.3(C-17),198.5(C-3),164.4(C-5),124.2(C-4),72.4(C-7),49.2(C-14),47.7(C-13),46.1(C-8) ,46.0(C-9),45.2(C-6),40.9(C-10),36.1(C-2),35.5(C-16),31.1(C-12),26.1(C-1),25.1(C-11),24.6(C-15),13.7(C-18).

[0094] 1.2 Verification of rescreening function

[0095] E. coli containing the mutants were streaked onto solid LB plates containing 50 μg / mL kanamycin and cultured overnight at 37°C. Single colonies were selected and transferred to 2 mL of liquid LB medium containing 50 μg / mL kanamycin and cultured overnight at 37°C with shaking. 500 μL of the bacterial solution was inoculated into a 100 mL Erlenmeyer flask containing 50 mL of TB medium and cultured on a shaker at 37°C and 220 rpm. When the absorbance of the culture solution reached OD 600When the p-value reached 0.8, IPTG was added to a final concentration of 0.2 mM to induce expression at 25°C for 16-20 hours. The culture was centrifuged at 4000 rpm and 4°C for 10 minutes, and the cells were harvested, washed once with 100 mM potassium phosphate buffer (pH 8.0), and stored at -80°C.

[0096] The cells were washed with 10 mL of 100 mM potassium phosphate buffer (pH 8.0, containing 5% w / v glucose, 5% v / v glycerol, 0.2 mM NADP + , 10U GDH) was resuspended in a 50mL centrifuge tube and immediately quick-frozen in liquid nitrogen. It was then placed in water and thawed at room temperature until thawed, 5mL of the bacterial suspension was taken into a 50mL Erlenmeyer flask, 5g / L methyldione or 5g / L androstenedione or 5g / L of 4,9 (prepared into a 200mM mother solution with DMF) was added, and the reaction was carried out at 25°C and 220rpm for 24 hours. Samples were taken at intervals, extracted with methanol, centrifuged at high speed for 1min, filtered with a 0.22μm filter membrane into a sample injection bottle, and the conversion rate and product distribution of the reaction were detected by HPLC. After 24h of reaction, the conversion rate of the substrate was 43%, the titer (concentration) of C7β-hydroxymethyldione was 2.2g / L, and the selectivity of C7β hydroxylation was 97%. The mutant was sent to a sequencing company for sequencing and was confirmed to be LG-23 / T260G, that is, the threonine at amino acid position 260 was mutated to glycine. Its amino acid sequence is shown in SEQ ID NO: 1, and its nucleotide sequence is shown in SEQ ID NO: 4.

[0097] According to the method described above, LG-23 / T260G was induced to express, and the cells were washed with 10 mL of 100 mM potassium phosphate buffer (pH 8.0, containing 5% w / v glucose, 5% v / v glycerol, 0.2 mM NADP) and 10 mL of 100 mM potassium phosphate buffer (pH 8.0, containing 5% w / v glucose, 5% v / v glycerol, 0.2 + , 10U GDH) was resuspended in a 50mL centrifuge tube and immediately quick-frozen in liquid nitrogen. It was then placed in water and thawed at room temperature until thawed. 5mL of the bacterial suspension was taken into a 50mL Erlenmeyer flask and 5g / L androstenedione or 5g / L 4,9-substance (prepared to a 200mM stock solution in DMF) was added. After 24 hours of reaction, the conversion rate of the substrate was 43%. At this time, the titer of C7β-hydroxyandrostenedione was 2.3g / L, and the selectivity of C7β hydroxylation was 97%; the titer of C11α-hydroxy 4,9-substance was 1.3g / L, and the selectivity of C11α hydroxylation was 95%.

[0098] Example 2: Functional verification of mutant LG-23 / T260G in different cosolvents

[0099] Dimethyl sulfoxide (DMSO), methanol, acetone, olive oil, and hydroxypropyl-β-cyclodextrin were used as cosolvents to dissolve the substrate methyldiketone. When using hydroxypropyl-β-cyclodextrin as a cosolvent, cyclodextrin was weighed at a mass ratio of methyldiketone:hydroxypropyl-β-cyclodextrin of 1:8 (final cyclodextrin concentration of 22% w / v). An appropriate amount of 100 mM potassium phosphate buffer, pH 8.0, was added to dissolve the cyclodextrin. Tween 80 was then added to a final concentration of 0.1% w / v, along with the substrate. Finally, an ultrasonic probe was used to further fragment the methyldiketone crystals. The solution was then thoroughly mixed to facilitate dissolution of the methyldiketone, resulting in a 100 mM methyldiketone-cyclodextrin solution at pH 8.0.

[0100] Using GDH and glucose as the cofactor circulation system, a whole-cell catalytic reaction system was constructed according to the method described in Example 1. 5 g / L methyl diketone was added with different cosolvents for reaction. Samples were taken at 2 h and 6 h of reaction. The catalytic reaction of LG-23 / T260G in different cosolvents is shown in Figure 2. Figure 2 It was found that using hydroxypropyl-β-cyclodextrin as a cosolvent had the best reaction effect. The conversion rate of methyl diketone catalyzed by LG-23 / T260G reached 83%, and the titer of C7β-hydroxymethyl diketone reached 3.43g / L. Compared with using DMF as a cosolvent, the product titer increased by 1.4 times and was twice that of using acetone as a cosolvent.

[0101] Example 3: Functional verification of the mutant LG-23 / T260G in different cofactor regeneration systems

[0102] Glucose dehydrogenase is derived from Priestia megaterium. The GDH gene is expressed alone, and the crude enzyme from the supernatant of the bacterium is used to catalyze the regeneration and recycling of the cofactor NADPH. The catalytic equation is: glucose + NADP + →Gluconolactone + NADPH.

[0103] Alcohol dehydrogenase TbADH (from Thermoanaerobacter brockii) and isopropanol dehydrogenase mutant IPADHM4 (from Brucella suis ATCC 23445) were selected as candidate dehydrogenases in the cofactor cycle system. Both ADHs can use isopropanol as an alcohol donor to produce acetone without affecting the pH of the reaction system. To reduce the impact of organic reagents on the reaction system, 1% v / v isopropanol was added to the reaction system as an alcohol donor. The catalytic equation is: isopropanol + NADP + →Acetone + NADPH.

[0104] The strains E. coli BL21 (DE3)-pRSFDuet-TbADH and E. coli BL21 (DE3)-pRSFDuet-IPADHM4 were induced to express according to the above method. The cell pellet obtained after the bacteria were harvested was adjusted to OD 0. 600 =20 cell suspension. Use cell ultrasonic disruptor to disrupt it, take the enzyme supernatant obtained after centrifugation to measure its activity. According to the NADPH measurement method, use spectrophotometer to measure the amount of NADPH generated. + The activity of the enzyme supernatant of E. coli BL21 (DE3)-pRSFDuet-IPADHM4 towards NADP+ was 77.6 U / mL, and the activity of the enzyme supernatant of E. coli BL21 (DE3)-pRSFDuet-IPADHM4 towards NADP+ was 4300 U / mL.

[0105] The mutant strain LG-23 / T260G whole-cell catalytic reaction was used to compare the matching effects of three dehydrogenases: GDH, TbADH, and IPADHM4. 10 g / L of methyldiketone solution (dissolved in cyclodextrin) was added to each reaction. Under the condition of adding 1 U / mL of enzyme, the use of GDH and glucose as the cofactor regeneration system had the highest product titer, and the titer (concentration) of C7β-hydroxymethyldiketone reached 4.4 g / L. However, after 8 hours of reaction, the reaction no longer proceeded, and the pH of the reaction system was 5.6. Using ADH and isopropanol as the cofactor regeneration system, the titer of C7β-hydroxymethyldiketone reached 3.6 g / L and 3.4 g / L, but after 8 hours of reaction, the P450BM3 mutant was still playing a role, at which time the pH was 7.8, which did not change significantly compared to pH 8.0. As the enzyme activities of added glucose dehydrogenase and isopropanol dehydrogenase reached 5U / mL and 10U / mL in the reaction system, the use of IPADHM4 and isopropanol as the cofactor regeneration system performed best. The titer of C7β-hydroxymethyldione reached 6.8g / L, which was 1.6 times that of the regeneration system using GDH and glucose as cofactors. The pH value did not change significantly, which proved the feasibility of using ADH and isopropanol as the cofactor regeneration system.

[0106] Example 4: Construction and functional verification of the mutant LG-23 / T260G and isopropanol dehydrogenase co-expression strain

[0107] 4.1 Construction of a recombinant expression vector for co-expressing LG-23 / T260G enzyme and IPADHM4 enzyme

[0108] Using the pRSFDuet-LG-23 / T260G mutant plasmid as a template, the plasmid was reversely amplified using primers containing an RBS (ribosome binding site) and a 20 bp homology arm, resulting in a fragment containing the RBS and homology arm, which is fragment 1. Using the pRSFDuet-IPADHM4 plasmid as a template, the IPADHM4 gene was amplified using a primer containing an RBS (containing a 20 bp homology arm) upstream and a primer containing a T7 terminator (containing a 20 bp homology arm) downstream, resulting in fragment 2. The primers used are shown in Table 2.

[0109] The PCR system (20 μL) was as follows: 0.1-1 ng of template, 1 μL of each pair of mutation primers (10 μM), 5 μL of PrimeSTARMax DNA polymerase, and sterile distilled water was added to 20 μL.

[0110] Table 2: Primers used to construct a recombinant expression vector co-expressing LG-23 / T260G enzyme and IPADHM4 enzyme

[0111]

[0112] Note: The suffix "F" in the primer name stands for forward; "R" stands for reverse. The same applies below.

[0113] The target fragments 1 and 2 were detected and recovered by gel electrophoresis, and their concentrations were measured using a micro-spectrophotometer. According to the T5 exonuclease ligation system, the 5' end of the homology arm was cut using T5 exonuclease to connect the two PCR fragments with homology ends. The reaction system was placed on ice. After 4 minutes of reaction, 4 μL of the reaction system was taken and the DNA was transferred to 100 μL E.coli DH5α by chemical conversion. Then, the whole was coated on LB (50 μg / mL Kan). + ) plate, and then placed in a 37℃ incubator for overnight culture. Single colonies were picked from the plate and inoculated into 2mL LB medium (Kan + , 50μg / mL) and numbered. After incubation at 37°C, 220rpm in a shaker for 6 hours, a small amount of bacterial suspension was aspirated for colony PCR verification. For strains containing the target band, 1mL of bacterial suspension was sampled for sequencing. Strains with correct sequencing and successful construction of the target plasmid were extracted using a plasmid miniprep kit and transformed into E. coli BL21(DE3) by electroporation to obtain the target recombinant E. coli expression strain, named E. coli-pRSFDuet-LG-23 / T260G_IPADHM4. Figure 3, where A is the LG23 / T260G expression plasmid map, B is the plasmid map for co-expression of LG23 / T260G and IPADHM4, and C is the SDS gel electrophoresis image of the supernatant of co-expression cell disruption.

[0114] 4.2 Co-expression functional verification

[0115] For the cell culture method, refer to the functional verification section of Example 1. During the reaction, the co-expression cells were taken out of the -80°C refrigerator, centrifuged after thawing, and resuspended in a 50 mL centrifuge tube using a 27.2 g / L methyldione solution (substrate dissolved in cyclodextrin) at pH 8.0. The cell concentration was adjusted to OD 600 = 60. Then take 5mL of bacterial suspension into a 50mL Erlenmeyer flask, add 1% v / v isopropanol and 10uL 50mM NADP + , reacted at 25°C, 220rpm for 24 hours. Samples were taken at intervals, extracted with methanol, centrifuged at high speed for 1 minute, filtered into a sample injection bottle with a 0.22μm filter membrane, and the conversion rate and product distribution of the reaction were detected by HPLC. After 20 minutes of reaction, the titer of C7β-hydroxymethyldione reached 2.1g / L; after 24 hours of reaction, the titer of C7β-hydroxymethyldione reached 12.9g / L. In addition, without the addition of NADP + In the case of , it has the same effect.

[0116] Example 5: Site-directed mutagenesis and functional verification of mutant LG-23 / T260G

[0117] 5.1 Site-directed mutagenesis of LG-23 / T260G

[0118] Site-directed mutagenesis was performed on several key amino acids at the entrance of the substrate channel in the enzyme model. The plasmid vector pRSFDuet-LG-23 / T260G_IPADHM4 expressing mutant LG-23 / T260G and isopropanol dehydrogenase was used as a template. The gene of mutant LG-23 / T260G was subjected to site-directed mutagenesis using primer PCR mutagenesis technology, and W47, Y51, and I401 were mutated to target amino acids. The primers used are shown in Table 3.

[0119] The PCR system (20 μL) was as follows: 0.1-1 ng of template, 1 μL of each pair of mutation primers (10 μM), 5 μL of PrimeSTARMax DNA polymerase, and sterile distilled water was added to 20 μL.

[0120] The amplified PCR product was examined by 0.7% agarose gel electrophoresis, and a band of comparable length to that of the pRSFDuet-LG-23 / T260G_IPADHM4 plasmid was observed, indicating that the gene encoding the target mutant had been amplified. Therefore, the restriction endonuclease Dpn I was directly added to the PCR product and digested at 37°C for 3-5 hours. The product was then transformed into E. coli BL21 (DE3) competent cells, revived in culture medium for 1 hour, and evenly plated onto solid LB plates containing 50 μl / mg kanamycin. After overnight incubation at 37°C, single colonies were selected and cultured in 3 mL of LB liquid medium containing 50 μl / mg kanamycin. The cells were then sent to a sequencing company for sequencing, resulting in the correct mutants, which were then named. The resulting mutants are listed in Table 3, and the PCR primers used are listed in Table 4.

[0121] Table 3: Mutants constructed using LG-23 / T260G as template

[0122]

[0123] Table 4: Site-directed mutagenesis primers for mutant LG-23 / T260G

[0124]

[0125] 5.2 Functional Verification

[0126] For the cell culture method, refer to the functional verification section of Example 1. During the reaction, the cells of each strain were taken out from the -80°C refrigerator, centrifuged after thawing, and resuspended in a 50 mL centrifuge tube using a 27.2 g / L methyldione solution (the substrate was dissolved in cyclodextrin) at pH 8.0. The cell concentration was adjusted to OD 600 =60. Subsequently, 5 mL of the bacterial suspension was transferred to a 50 mL Erlenmeyer flask, 1% v / v isopropanol was added, and the reaction was continued at 25°C and 220 rpm for 24 hours. Samples were taken at intervals, extracted with methanol, centrifuged at high speed for 1 minute, and filtered through a 0.22 μm filter into a sample injection bottle. HPLC was used to analyze the conversion rate and product distribution of the catalytic reaction of each strain. The results showed that compared with LG-23 / T260G, its mutant LG-23 / Y51I / T260G had further improved catalytic activity. After 24 hours of reaction, the titer of C7β-hydroxymethyldione reached 16.7 g / L. Its amino acid sequence is shown in SEQ ID NO: 2, and its nucleotide sequence is shown in SEQ ID NO: 5.

[0127] Example 6: Site-directed mutagenesis and functional verification of mutant LG-23 / Y51I / T260G

[0128] 6.1 Site-directed saturation mutagenesis of LG-23 / Y51I / T260G

[0129] Targeting the substrate molecule outlet channel in the enzyme model, the following amino acids surrounding the LG-23 / Y51I / T260G channel were selected for saturation site-directed mutagenesis: F107, I153, G157, and F405. Using the plasmid vector pRSFDuet-LG-23 / Y51I / T260G and isopropanol dehydrogenase expressing mutant LG-23 / Y51I / T260G_IPADHM4 as a template, the LG-23 / Y51I / T260G gene was subjected to site-directed mutagenesis using primer-based PCR mutagenesis. The amino acids F107, I153, G157, and F405 were subjected to site-directed saturation mutagenesis. The primers used are listed in Table 5.

[0130] Table 5: Site-directed saturation mutagenesis primers for mutant LG-23 / Y51I / T260G

[0131]

[0132] PCR amplification and mutant strain screening were performed according to the method of Example 1, and mutant strains with significantly improved enzyme activity in catalyzing the C7β hydroxylation reaction of methyldiketone compared with LG-23 / Y51I / T260G were selected for rescreening and functional verification.

[0133] 6.2 Functional Verification

[0134] The functions of each mutant strain were verified according to the method described in Example 5.2.

[0135] During the reaction, cells of each strain were taken out of the -80°C refrigerator, centrifuged after thawing, the supernatant was discarded, and resuspended in a 50 mL centrifuge tube using a 27.2 g / L methyldione solution (the substrate was dissolved in cyclodextrin) at pH 8.0. The cell concentration was adjusted to OD 600 =60. Subsequently, 5 mL of the bacterial suspension was taken into a 50 mL Erlenmeyer flask, 1% v / v isopropanol was added, and the reaction was carried out at 25°C and 220 rpm for 24 hours. Samples were taken at intervals, extracted with methanol, centrifuged at high speed for 1 minute, and filtered through a 0.22 μm filter membrane into a sample injection bottle. HPLC was used to detect the conversion rate and product distribution of the catalytic reaction of each strain. Among all the rescreened strains, the mutant LG-23 / Y51I / G157S / T260G was found to have higher catalytic activity. After 24 hours of reaction, the titer of C7β-hydroxymethyldione reached 22.4 g / L. Its amino acid sequence is shown in SEQ ID NO: 3, and its nucleotide sequence is shown in SEQ ID NO: 6.

[0136] Example 7: Investigation of the catalytic activity of cytochrome P450BM3 mutants on other steroid compounds

[0137] According to the method described in Example 1, the co-expression strains expressing the mutants LG-23, LG-23 / T260G, LG-23 / Y51I / T260G, and LG-23 / Y51I / G157S / T260G and expressing isopropanol dehydrogenase were induced to express.

[0138] The catalytic ability and position specificity of the cells of these strains in catalyzing the hydroxylation reactions of substrates methyldione, androstenedione, 4,9-dione, 18-methadione, adrenosterol, testosterone, and nandrolone were investigated.

[0139] During the reaction, the cells were taken out of the -80℃ refrigerator, centrifuged after thawing, and resuspended in 50mL centrifuge tubes with different steroid compounds at pH 8.0. The cell concentration was adjusted to OD 600 =60. All steroidal substrates were dissolved in cyclodextrin and Tween using the same method as in Example 1. Subsequently, 5 mL of the bacterial suspension containing 30 g / L of the steroid compound was placed in a 50 mL Erlenmeyer flask, 2% v / v isopropanol was added, and the reaction was carried out at 25°C and 220 rpm for 24 hours. Samples were taken at intervals, extracted with methanol, centrifuged at high speed for 1 minute, and filtered through a 0.22 μm filter into a sample injection vial. HPLC was used to determine the conversion rate and product distribution of the reaction. The conversion of the substrates by the different mutant strains is shown in Table 6.

[0140] Table 6: Catalytic activity of P450BM3 mutants towards different steroid compounds

[0141]

[0142]

[0143] The results showed that the mutants LG-23 / T260G, LG-23 / Y51I / T260G and LG-23 / Y51I / G157S / T260G could not only catalyze the position-specific hydroxylation reactions of methyldione, androstenedione, and 4,9-dione, but also catalyze the hydroxylation reactions of other steroid substrates such as 18-methyldione, adrenosterone, testosterone, and nandrolone, while maintaining high positional specificity, proving that these mutants have a broad substrate spectrum and show potential for industrial application.

[0144] The above description is only a preferred specific embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any changes or substitutions that can be easily thought of by any technician familiar with this technical field within the technical scope disclosed by the present invention should be covered by the scope of protection of the present invention.

Claims

1. A cytochrome P450BM3 mutant, characterized in that: It is a mutant formed after one or more of the following sites in the initial cytochrome P450BM3 amino acid sequence SEQ ID NO: 7 are mutated: Y51, G157, T260. The cytochrome P450BM3 mutant has the function of catalyzing the reaction of methyl diketone, androstenedione or 4,9-compound to generate C7β-hydroxymethyl diketone, C7β-hydroxyandrostenedione or C11α-hydroxy 4,9-compound.

2. The cytochrome P450BM3 mutant according to claim 1, characterized in that It is a mutant formed by one or more mutations selected from the following group in the initial cytochrome P450BM3 amino acid sequence SEQ ID NO: 7: Y51I, G157S, T260G.

3. The cytochrome P450BM3 mutant according to claim 2, characterized in that Its amino acid sequence is SEQ ID NO: 1, which is a T260G mutant of the amino acid sequence SEQ ID NO: 7; its amino acid sequence is SEQ ID NO: 2, which is a Y51I / T260G mutant of the amino acid sequence SEQ ID NO: 7; its amino acid sequence is SEQ ID NO: 3, which is a Y51I / G157S / T260G mutant of the amino acid sequence SEQ ID NO:

7.

4. A gene encoding the cytochrome P450BM3 mutant according to any one of claims 1 to 3.

5. The gene according to claim 4, characterized in that The nucleotide sequence of the gene encoding the cytochrome P450BM3 mutant amino acid sequence SEQID NO:1 is SEQ ID NO:4, the nucleotide sequence of the gene encoding the cytochrome P450BM3 mutant amino acid sequence SEQID NO:2 is SEQ ID NO:5, and the nucleotide sequence of the gene encoding the cytochrome P450BM3 mutant amino acid sequence SEQID NO:3 is SEQ ID NO:

6.

6. A plasmid comprising the gene according to claim 5.

7. A microorganism for expressing the cytochrome P450BM3 mutant according to claim 3, preferably the microorganism is a transformant transformed with the plasmid according to claim 7.

8. The microorganism according to claim 7, characterized in that Selected from Escherichia coli, Bacillus subtilis, Pichia pastoris, Saccharomyces cerevisiae, preferably Escherichia coli, more preferably Escherichia coli BL21 (DE3).

9. Use of the cytochrome P450BM3 mutant according to any one of claims 1 to 3 or the microorganism according to claim 8 in producing steroidal compounds.

10. The use according to claim 9, characterized in that Using methyl diketone, androstenedione or 4,9-compound as substrate, the cytochrome P450BM3 mutant or the microorganism is used to catalyze the hydroxylation reaction to generate the corresponding hydroxylated steroid C7β-hydroxymethyl diketone, C7β-hydroxyandrostenedione or C11α-hydroxy 4,9-compound: Alternatively, 18-methadione, adrenosterone, testosterone or nandrolone are used as substrates, and the cytochrome P450BM3 mutant or the microorganism is used to catalyze the hydroxylation reaction to generate the corresponding hydroxylated steroid C7β-hydroxy-18-methadione, C7β-hydroxyadrenosterone, C7β-hydroxytestosterone or C7β-hydroxynandrolone:

Citation Information

Patent Citations

  • Cytochrome P450BM3 oxidase mutant as well as preparation method and application thereof

    CN112760298A

  • Cytochrome P450 BM3 mutant and application thereof in synthesis of trenbolone acetate

    CN113528472A

Cited By

  • Cytochrome P450BM3 mutant, carrier, microorganism and application of cytochrome P450BM3 mutant

    CN118995644A

  • 17beta-hsdcl enzyme mutants, vectors, microorganisms and uses thereof

    CN118995644B

  • Application of cytochrome P450BM3 mutant in synthesis of altrenogest

    CN119799661A

  • Use of a cytochrome p450 bm3 mutant in the synthesis of allylprogesterone

    CN119799661B

  • Non-cofactor-dependent P450BM3 mutant and application thereof in degradation of lignin-derived phenols

    CN121065117A